Evidence map›Paper›PMID 35546171›Full record

ArticleScientific reports2022

On Methods for the Measurement of the Apelin Receptor Ligand Apelin.

Peter Janssens, Henriette de Loor, Jean-Paul Decuypere, Rudi Vennekens, Catherine Llorens-Cortes, Djalila Mekahli, Bert Bammens

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The Apelinergic System in Kidney Disease: Novel Perspectives.International journal of molecular sciences · 2025
    Review
  6. The role of apelin in cancer.Frontiers in oncology · 2025
    Review
  7. Review
  8. Apelin is altered in subjects with autosomal dominant polycystic kidney disease and preserved kidney function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Peter Janssens *PKD Research Group, Laboratory of Pediatrics, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Peter.janssens@uzbrussel.be.
Henriette de Loor *Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. jetty.deloor@uzleuven.be.
Jean-Paul DecuyperePKD Research Group, Laboratory of Pediatrics, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Rudi VennekensLaboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, Biomedical Sciences Group, KU Leuven, Leuven, Belgium.
Catherine Llorens-CortesLaboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, Center for Interdisciplinary Research in Biology, Collège de France, INSERM U1050/CNRS UMR 7241, Paris, France.
Djalila Mekahli *PKD Research Group, Laboratory of Pediatrics, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Bert Bammens *Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
KU Leuven · BEInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apelin exists in many isoforms, both in the circulation and in specific tissues. Apelin peptides have a short half-life but preservation before measurement is scarcely studied. Reproducible mass spectrometry methods to specifically measure a broad range of apelinergic peptide isoforms are currently lacking. A sample protocol to conserve apelinergic peptides in the preanalytical phase and a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to measure apelinergic isoforms was developed. Apelin was measured in plasma. For validation, human embryonic kidney (HEK) cells transfected with cDNA for preproapelin were used. Results were compared with a validated radioimmunoassay (RIA) method. Acidifying plasma to pH 2.5 improves post-sampling stability of apelin. HPLC-MS/MS was unable to detect apelin isoforms in plasma of healthy volunteers (n = 16) and chronic kidney disease patients (n = 4). RIA could detect apelin in concentrations between 71 and 263 fmol/l in 10 healthy volunteers. An optimized preanalytical protocol was developed. A sensitive and specific HPLC-MS/MS method failed to detect apelin in human plasma. Apelin-36 was detected in HEK cells transfected with cDNA for preproapelin. Currently, RIA with relatively selective antibodies is the best alternative for the measurement of apelin but novel sensitive and specific methods are needed.

Indexed as

Intercellular Signaling Peptides and ProteinsTandem Mass SpectrometryApelinApelin ReceptorsDNA, ComplementaryHumansLigandsPeptidesProtein IsoformsApelinApelin ReceptorsDNA, ComplementaryIntercellular Signaling Peptides and ProteinsLigandsPeptidesProtein Isoforms

Identifiers

PMID35546171
PMCPMC9095593
OpenAlexW4280521409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.